Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes
I'm PortAI, I can summarize articles.
Eledon Pharmaceuticals announced promising preliminary results for tegoprubart, an investigational anti-CD40L antibody, in an islet transplant trial for type 1 diabetes. Conducted at the University of Chicago Medicine’s Transplant Institute, the trial showed all six patients in the preliminary cohort achieved insulin independence. The study is funded by Breakthrough T1D, with further research support committed. Results were presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium in Los Angeles.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments